Zhang Lianru, Zhou Xipeng, Sha Huizi, Xie Li, Liu Baorui
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Department of oncology, Yizheng People's Hospital, Yangzhou, China.
Front Oncol. 2022 Jun 6;12:905832. doi: 10.3389/fonc.2022.905832. eCollection 2022.
Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward.
乳腺癌仍然是全球最常被诊断出的恶性肿瘤。晚期乳腺癌仍然是一种无法治愈的疾病,主要原因在于其异质性和有限的免疫原性。癌症免疫疗法的巨大成功为癌症治疗的新时代铺平了道路,治疗性癌症疫苗接种是一个备受关注的领域。疫苗靶点包括肿瘤相关抗原和肿瘤特异性抗原。不同的疫苗递送平台引发的免疫反应有所不同。下一代测序技术和计算分析最近使个性化疫苗接种成为可能。然而,在乳腺癌中,仅有少数受益于基于新抗原治疗的病例被报道,并且更多的关注集中在基于过表达抗原的治疗上,尤其是人表皮生长因子2衍生肽疫苗。在此,我们讨论乳腺癌治疗性疫苗的最新进展,并强调近期向前发展的机遇。